 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jun 29, 2022 |
| Title |
Identification of Pathogenic Immune Cell Subsets in Checkpoint Inhibitor-induced Myocarditis |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Other
|
| Summary |
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used widely to activate the immune system against tumor cells. Despite their therapeutic benefits, ICIs are known to cause immune-related adverse events (irAE) such as myocarditis, a rare but serious side effect with up to 50% mortality. To identify pathogenic immune subset(s) responsible for ICI myocarditis and other irAE, we performed single cell mass cytometry (CyTOF) on peripheral blood mononuclear cells from 40 patients and controls with irAE including four patients with ICI myocarditis. We also profiled 15 patients/controls using single cell RNA sequencing (scRNA-seq) with feature barcoding for surface marker expression confirmation. In both CyTOF/scRNAseq analyses, we found expansions of cytotoxic CD8+ T effector cells re-expressing CD45RA (Temra CD8+ cells) in ICI myocarditis patients compared to controls. Using T cell receptor sequencing, we demonstrated a significant clonal expansion of CD8+ Temra cells in myocarditis patients. Transcriptomic profiling of these Temra CD8+ clones confirmed their highly activated and cytotoxic phenotype with expression of granzyme/perforin. Longitudinal data revealed the progression of these Temra CD8+ cells into an exhausted phenotype two months after diagnosis of myocarditis and after treatment with glucocorticoids. Differential expression of several proinflammatory chemokines (CCL4/CCL4L2/CCL5) was uncovered in the clonally expanded Temra CD8+ cells and ligand-receptor analysis implicated their regulation of other inflammatory cells such as monocytes and NK cells. These data suggest that the therapeutic modulation of these chemokines may serve as an attractive strategy for reducing life-threatening irAE in ICI-treated cancer patients.
|
| |
|
| Overall design |
PBMCs were collected and isolated from three main patient groups: Group A - patients on immune checkpoint inhibitors without any known immune adverse events (irAEs), Group B - patients on immune checkpoint inhibitors with non-myocarditis irAEs, Group C - patients on immune checkpoint inhibitors with myocarditis. High-throughput sequencing in the form of scRNA-seq, single cell TCR sequencing, and feature barcoding were then performed. CyTOF (mass cytometry) data was also obtained on samples (not included on this record).
The processed data for the CITE-seq component are included in the single-cell RNA-seq sample data matrices..
|
| |
|
| Contributor(s) |
Zhu H, Wu S |
| Citation(s) |
35762356 |
| |
| Submission date |
Jul 13, 2021 |
| Last update date |
Nov 29, 2022 |
| Contact name |
Han Zhu |
| E-mail(s) |
hanzhu@stanford.edu
|
| Organization name |
Stanford University
|
| Department |
Cardiovascular Medicine
|
| Lab |
Sean Wu Lab
|
| Street address |
G1105, 265 Campus Drive
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (65)
|
|
| Relations |
| BioProject |
PRJNA746332 |
| SRA |
SRP328212 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE180045_RAW.tar |
1.6 Gb |
(http)(custom) |
TAR (of CSV, TAR) |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...